Corporate Governance

Investors Menu

Leadership Team

Scott Tarriff, Founder, Chief Executive Officer and Director

Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.

Scott currently sits on the board of directors of Synthetic Biologics, Inc., Ziopharm Oncology, Inc., Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.

David Pernock, President, Chief Operating Officer

David has been our President and Chief Commercial Officer since January 2017. David brings a wealth of pharmaceutical and biotechnology experience to the Eagle leadership team, having previously served as a member of the board from April 2015 through December 2016. David’s strategic focus and entrepreneurial spirit has contributed to the commercial success of many products throughout his distinguished career.

Before joining Eagle, David served as Chairman of the board of directors and CEO (2010-2017) of Fibrocell Science, Inc., a publicly traded autologous cell and gene therapy company.

David previously held various positions at GlaxoSmithKline, most notably serving as Senior Vice President of the Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions. He also served as President of Reliant Pharmaceuticals and as a director of Martek Biosciences Corporation.

David holds a BS in business administration from Arizona State University.

Pete A. Meyers, Chief Financial Officer

Pete joined Eagle in May 2017 with more than 2 decades of experience in the healthcare industry. From 2016 to 2017, he served as Chief Financial Officer of Motif BioSciences, Inc. Prior to joining Motif, Pete spent 3 years as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation.

Pete has 18 years of experience as a healthcare investment banker, including Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Pete currently serves on the board of directors and chairs the Audit Committee of Immutep Ltd.

Pete holds a BS in finance from Boston College and an MBA in finance from Columbia Business School.

Michael W. Cordera, Executive Vice President, General Counsel and Chief Compliance Officer

Mike joined Eagle in April 2016 as Deputy General Counsel and was promoted to General Counsel and Chief Compliance Officer in March 2018. Prior to joining Eagle, he held various legal positions with increasing responsibility at Warner Chilcott plc (2010–2014) and inVentiv Health (2014–2016).

From 2001 until 2009, Mike was an associate at Shearman & Sterling LLP, where he focused on litigation and finance.

Mike earned a BA in international affairs from The American University of Paris and his JD from Rutgers School of Law—Newark.

Daniel O'Connor, Chief Strategy Officer, Head of Corporate Development

Dan is our Executive Vice President of Biologics and Corporate Development. Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure.

Prior to joining Eagle in 2007, Dan held a variety of management positions, such as Senior Analyst at Ethicon (a Johnson & Johnson Company subsidiary) and Lead Finance Liaison throughout Ethicon’s joint venture with Omrix Biopharmaceuticals. Dan additionally held several finance positions at Ranbaxy Pharmaceuticals Inc. (a wholly owned subsidiary of Ranbaxy Inc.), which markets generic products in the US.

Dan holds a BS in business administration from West Virginia University and an MBA from Rutgers University.

Michael Moran, Executive Vice President, Sales, Business Development and Government Affairs

Mike joined Eagle in January 2016 as Vice President, Sales and was promoted to Executive Vice President, Sales, Business Development and Government Affairs in August 2019. Mike has a lengthy record of success in the pharmaceutical industry. Prior to joining Eagle, Mike held various positions with increasing responsibility at GlaxoSmithKline, Reliant Pharmaceuticals, Muro and Astra Zeneca.

Mike earned his B.S. in Business Management from the State University of New York at Empire and completed the Transformational Leadership for Executives program at the University of Pennsylvania Wharton School of Business.

Board of Directors

Michael Graves, Chairman of the Board, Executive Committee Chair, Nominating and Corporate Governance Committee Chair, Compensation Committee Chair

Mike has served as a member of Eagle’s board of directors since 2013. Mike is Chairman of the board of directors of Nanocopoeia, Inc., and a member of the board of directors of RiboCor, Inc. Mike has a wide variety of pharmaceutical industry experience including his position as CEO and President of Paddock Laboratories, Inc., and multiple leadership positions leading to President of the Generic Products Division at Par Pharmaceutical from 1998 to 2006.

Scott Tarriff, Founder, Chief Executive Officer and Director

Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.

Scott currently sits on the board of directors of Synthetic Biologics, Inc., Ziopharm Oncology, Inc., Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.

Richard A. Edlin,, J.D., Board Member, Compensation Committee, Nominating and Corporate Governance Committee

Rich is currently the Vice Chair, Chair of Litigation Practice in New York and the Business & Regulatory Financial Services Litigation Group, and a member of the Executive Committee of the law firm Greenberg Traurig, LLP.

Rich is a member of the Board of Trustees of the Urban Justice Center; a member of the Board of Directors for Judges and Lawyers Breast Cancer Alert (JALBCA); a member of the Board of Governors of Hackensack University Medical Center; a trustee of The Carnegie Council for Ethics in International Affairs; a member of the Board of Governors, American Friends of Tel Aviv University; a member of the Economic Club of New York; a fellow of the Litigation Council of America; and a trustee of New Jersey SEEDS, among other professional and community activities.

Robert L. Glenning, Board Member, Audit Committee, Nominating and Corporate Governance Committee

Bob has over 30 years of experience in the healthcare industry and currently serves as President of the Financial Services and Information Technology Divisions and CFO at Hackensack Meridian Health, the most comprehensive healthcare delivery network in the state of New Jersey. He previously served as Executive Vice President and CFO of Hackensack University Health Network. From 2002 to 2007, Bob served as EVP and CFO of Kaleida Health, Inc. Prior to Kaleida Health, he served as VP and CEO of Acute Care at Northeast Health and Albany Memorial Hospital. Robert began his career at PricewaterhouseCoopers.

Steven Ratoff, Board Member, Audit Committee Chair, Compensation Committee

Steve has served as a member of our board of directors since Eagle’s inception in 2007. From 2010, he has served as President and Chief Executive Officer of NovaDel Pharma, Inc., filling a number of executive positions since joining their board of directors in 2005, and is currently serving as its Chairman. Prior to NovaDel, Steve held various executive positions with Cima Labs, Inc., MacroMed, Inc., and Brown-Forman Corporation. In 2004, Steve began his ongoing tenure as a venture partner of ProQuest Investments.

Jennifer Simpson,, PhD, Board Member, Nominating and Corporate Governance Committee

Dr. Simpson has been President and CEO of Delcath and a member of the board since May 2015. She previously served as interim President and Chief Executive Officer, joining Delcath in 2012 as Executive Vice President, Global Marketing.

Prior to Delcath, Dr. Simpson served in positions of increasing responsibility at ImClone Systems (a subsidiary of Eli Lilly and Company), most recently as Vice President, Global Marketing, Oncology Brand Lead, where she was responsible for product commercialization activities and launch preparation for one of their late stage assets. Prior to ImClone, Dr. Simpson was Product Director, Oncology Therapeutics Marketing at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech focused on innovative solutions in immunology, oncology and nephrology.

Early in her career, she spent over a decade as a hematology/oncology nurse practitioner and educator. Dr. Simpson earned a Ph.D. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo.

Investor Contact

In-Site
Communications, Inc.
Lisa M. Wilson,
212-452-2793

For all other media inquiries, please contact us.